AKBA
Akebia Therapeutics, Inc.
AKBA lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
AKBA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Stable | |
| Strong |
AKBA's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are weak.
AKBA PE Valuation
AKBA has no meaningful PE right now: it lost money over the past year.
AKBA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect AKBA's losses to grow, with revenue declining. However, they disagree widely on these estimates.
AKBA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.16 | -$0.09 |
| Q2 2026 | -$0.11 | +$0.06 |
| Q1 2026 | -$0.08 | +$0.13 |
| Q4 2025 | -$0.02 | +$0.31 |
| Q3 2025 | -$0.07 | +$0.15 |
| Q2 2025 | -$0.17 | +$0.03 |
| Q1 2025 | -$0.21 | +$0.01 |
| Q4 2024 | -$0.33 | -$0.06 |
AKBA lost $0.16 per share over the past year, and its loss has widened in each of the last three quarters.
AKBA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $36.9M | -37% |
| Q2 2026 | $49.1M | -21% |
| Q1 2026 | $53.5M | -6.6% |
| Q4 2025 | $57.6M | +24% |
| Q3 2025 | $58.8M | +57% |
| Q2 2025 | $62.5M | +43% |
| Q1 2025 | $57.3M | +76% |
| Q4 2024 | $46.5M | -17% |
AKBA's revenue has slid since its 2022 peak: $37M last quarter, down 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -31% | -39 points |
| Q2 2026 | -13% | -35 points |
| Q1 2026 | -8.8% | -32 points |
| Q4 2025 | -15% | +16 points |
| Q3 2025 | 7.6% | +41 points |
| Q2 2025 | 23% | +43 points |
| Q1 2025 | 24% | +69 points |
| Q4 2024 | -31% | -33 points |
AKBA's operating margin was −31% last quarter, down 39 points from the same quarter a year ago.
AKBA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.6M | -94% |
| Q2 2026 | $2.4M | -89% |
| Q1 2026 | -$21.3M | -$7.7M |
| Q4 2025 | $31.1M | +$35.5M |
| Q3 2025 | $28M | +$34.7M |
| Q1 2025 | -$13.6M | +$5.8M |
| Q4 2024 | -$4.5M | -$2.2M |
| Q3 2024 | -$6.7M | +$470K |
AKBA has burned cash in most quarters: $14M over the past year, down 57% from the year before.
AKBA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +7.3M shares |
| 1 year | +0.9% | +2.5M shares |
| 3 years | +47% | +88.6M shares |
| 5 years | +59% | +103M shares |
| Available history | +132% | +158M shares |
AKBA has 277M diluted shares, up 0.9% from a year ago.
AKBA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -17.3x | Net Cash |
| Q4 2025 | -5.5x | Net Cash |
| Q3 2025 | -4.2x | Net Cash |
| Q2 2025 | -4.5x | Net Cash |
| Q1 2025 | -10.5x | Net Cash |
| Q3 2024 | 1.6x | Healthy |
AKBA has more cash than debt.
AKBA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 14.7 | Oversold |
AKBA's weekly RSI is 33 (neutral) and its Stochastic is 15 (oversold).
AKBA PE vs Healthcare Sector
AKBA has no meaningful PE right now: it lost money over the past year.
AKBA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.68 | 26% below |
| 20 week MA | $0.92 | 46% below |
| 50 week MA | $1.16 | 57% below |
| 100 week MA | $1.88 | 73% below |
| 200 week MA | $1.56 | 68% below |
AKBA is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
AKBA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.52 | $2.92 | -55% |
| 2021 | $2.92 | $2.53 | -13% |
| 2022 | $2.53 | $0.43 | -83% |
| 2023 | $0.43 | $1.24 | +188% |
| 2024 | $1.24 | $1.95 | +57% |
| 2025 | $1.95 | $1.66 | -15% |
| 2026 YTD | $1.66 | $0.50 | -70% |
AKBA's yearly returns have swung widely, from +188% in 2023 to −83% in 2022. It's down 70% so far in 2026.